布地奈德联合复方异丙托溴铵雾化吸入治疗COPD急性期的效果评价  

Effect of budesonide combined with compound ipratropium bromide inhalation on treatment of AECOPD

作　　者：林淑媚[1] 黄均贤 陈丽华[1] LIN Shu-mei;HUANG Jun-xian;CHEN Li-hua(Department of Respiratory and Critical Care Medicine,CHEN Xinghai Hospital of Zhongshan City,Guangdong 528415,China)

机构地区：[1]中山市陈星海医院呼吸与危重症医学科,广东528415

出　　处：《中国临床新医学》2018年第8期798-800,共3页CHINESE JOURNAL OF NEW CLINICAL MEDICINE

摘　　要：目的探讨慢性阻塞性肺疾病(COPD)急性期患者应用布地奈德联合复方异丙托溴铵雾化吸入治疗的临床效果。方法选择该院2014-10~2017-10接受治疗的300例COPD急性期患者作为观察对象,依据抽签法分为对照组和观察组,各150例。对照组应用复方异丙托溴铵雾化吸入治疗,观察组在对照组基础上应用布地奈德雾化吸入治疗。对两组临床疗效、治疗前后肺功能、血气指标变化及不良反应发生情况进行统计比较。结果观察组治愈85例,显效38例,有效19例,无效8例。对照组治愈67例,显效38例,有效15例,无效30例。观察组临床疗效明显优于对照组(P<0.01)。两组治疗后1s用力呼气容积(FEV1)、用力肺活量(FVC)、FEV1占预计值、血氧分压(Pa O2)水平升高,二氧化碳分压(Pa CO2)水平降低,与治疗前比较差异有统计学意义(P<0.05),且观察组FEV1、FVC、FEV1占预计值、Pa O2水平高于对照组,Pa CO2水平低于对照组(P<0.05)。观察组不良反应发生率为6.7%,与对照组的10.0%比较差异无统计学意义(P>0.05)。结论 COPD急性期患者应用布地奈德联合复方异丙托溴铵雾化吸入治疗的临床效果显著,不仅可以改善患者肺功能与血气指标,且不会增加不良反应,具有安全、可靠的优点。Objective To investigate the clinical effect of budesonide combined with compound ipratropium bromide inhalation on treatment of acute exacerbation of chronic obstructive pulmonary disease（AECOPD）. Methods Three hundred patients with AECOPD treated from October 2014 to October 2017 were selected as the observation subjects and divided into two groups according to the randomized drawing method： control group（n=150） and observation group（n=150）. The control group was treated with compound ipratropium bromide inhalation. The observation group received the same treatment as the control group plus budesonide inhalation. The clinical efficacy, lung function, changes of blood gas indexes and adverse reactions were compared between the two groups. Results The total clinical efficiency of the observation group（94.7%） was significantly higher than that of the control group（80.0%）（P〈0.05）. The forced expiratory volume（FEV1）, forced vital capacity（FVC）, predicted FEV1, PaO2 and PaCO2 in the two groups after 1-hour treatment were significantly lower than those before treatment（P〈0.05）. The levels of FEV1, FVC, FEV1 accounting for predicted value and PaO2 in the observation group were significantly higher than those in the control group（P〈0.05）. The level of PaCO2 in the observation group was significantly lower than that in the control group（P〈0.05）. There was no significant difference in the incidence of adverse reactions between the observation group（6.7%） and the control group（10.0%）（P〉0.05）. Conclusion Budesonide combined with compound ipratropium bromide inhalation is effective in treatment of AECOPD. It can improve pulmonary function and blood gas indexes, but does not increase adverse reactions.

关 键 词：慢性阻塞性肺疾病 布地奈德 复方异丙托溴铵 雾化吸入 临床疗效 

分 类 号：R56[医药卫生—呼吸系统]